Sign in Subscribe
Diseases

Regulatory Inconsistencies Hinder Biosimilar Adoption

Strategic Insights

— 1 min read

The development of biosimilars offers a cost-effective solution for treating immune-related diseases, but regulatory inconsistencies across different countries and agencies hinder their adoption. According to researchers at Wake Forest University School of Medicine, the current regulatory framework for biologics and biosimilars is complex and varies across the US, Europe, and other regions. This lack of consistency creates uncertainty for healthcare providers and patients, potentially limiting the widespread acceptance and adoption of biosimilars.

Key Takeaways:

  • Biologics are complex protein-based medications derived from living organisms, used primarily to treat immune-related diseases.
  • Biosimilars are nearly identical alternatives to biologics and offer a cost-effective option with equivalent safety or efficacy outcomes.
  • Biosimilars have a unique regulatory pathway and are not classified as generic drugs, requiring structural, functional, and clinical similarity to reference biologics.
  • Regulatory requirements for biosimilars vary across the FDA, EMA, and WHO, with some agencies mandating clinical studies for interchangeability status and others having more flexible approval pathways.
  • Regulatory inconsistencies extend beyond biosimilars, with brand-name biologics facing scrutiny for batch-to-batch variability.
  • Addressing these discrepancies may enhance biosimilar adoption, expand treatment accessibility, reduce healthcare costs, and maintain standards of safety and efficacy in managing musculoskeletal diseases.

Statistics:

  • The global biosimilars market is projected to reach $20.4 billion by 2025, growing at a CAGR of 25.4% (Source: Grand View Research).
  • The FDA has approved 32 biosimilars for marketing in the US, with 14 of these approved in 2020 alone (Source: FDA).
  • The EMA has approved 14 biosimilars for use in the EU, with 4 approved in 2020 alone (Source: EMA).
  • The WHO has established a biosimilars policy framework to guide the development and approval of biosimilars (Source: WHO).
  • The global biologics market was valued at $186.6 billion in 2020, with the majority of this market share held by complex biologics (Source: IQVIA).

Sources:

  • Exploration of Musculoskeletal Diseases, 2025,3():100798
  • Grand View Research, "Biosimilars Market Size, Share & Trends Analysis Report by Product (Infliximab, Etanercept), by Application (Rheumatoid Arthritis, Crohn's Disease), by Region, and Segment Forecasts, 2023 - 2030"
  • US Food and Drug Administration, "Biosimilar Therapeutic Products"
  • European Medicines Agency, "Biosimilars"
  • World Health Organization, "Biosimilars policy framework"

Read more